CD40 and B-cell non-Hodgkin lymphoma: Importantly, this difference in immunostimulatory capacity correlated with differences in therapeutic activity where 3/23 h2, but not 3/23 h1, provided protection against tumor development in both a vaccination setting where mice immunized with OVA plus anti-CD40 were challenged with the OVA-expressing EG7 tumor (Figure 1G) and a therapeutic setting where mice with established B cell lymphoma (BCL1 lymphoma model [White et al., 2014]; Figure 1H) were treated with a single 100 μg dose of mAb.